Guerbet SA
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solut… Read more
Market Cap & Net Worth: Guerbet SA (4G8)
Guerbet SA (F:4G8) has a market capitalization of $102.04 Million (€99.41 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #21988 globally and #2388 in its home market, demonstrating a -33.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guerbet SA's stock price €7.88 by its total outstanding shares 12615123 (12.62 Million).
Guerbet SA Market Cap History: 2015 to 2026
Guerbet SA's market capitalization history from 2015 to 2026. Data shows change from $666.73 Million to $102.04 Million (-16.21% CAGR).
Guerbet SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guerbet SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.42x
Guerbet SA's market cap is 0.42 times its annual revenue
0.67x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
22.14x
Guerbet SA's market cap is 22.14 times its annual earnings
1.94x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $666.73 Million | $489.91 Million | $39.23 Million | 1.36x | 16.99x |
| 2016 | $769.99 Million | $776.47 Million | $28.93 Million | 0.99x | 26.62x |
| 2017 | $869.40 Million | $808.63 Million | $46.22 Million | 1.08x | 18.81x |
| 2018 | $583.17 Million | $794.61 Million | $46.82 Million | 0.73x | 12.46x |
| 2019 | $481.09 Million | $819.00 Million | $37.33 Million | 0.59x | 12.89x |
| 2020 | $386.64 Million | $716.67 Million | $17.71 Million | 0.54x | 21.83x |
| 2021 | $441.49 Million | $735.91 Million | $32.64 Million | 0.60x | 13.53x |
| 2022 | $211.14 Million | $769.50 Million | -$41.12 Million | 0.27x | N/A |
| 2023 | $246.08 Million | $795.65 Million | $23.87 Million | 0.31x | 10.31x |
| 2024 | $356.10 Million | $851.12 Million | $16.08 Million | 0.42x | 22.14x |
Competitor Companies of 4G8 by Market Capitalization
Companies near Guerbet SA in the global market cap rankings as of March 19, 2026.
Key companies related to Guerbet SA by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #84 globally with a market cap of $187.53 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #151 globally with a market cap of $119.88 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #170 globally with a market cap of $111.60 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #183 globally with a market cap of $105.38 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #84 | Abbott Laboratories | NYSE:ABT | $187.53 Billion | $108.49 |
| #151 | Stryker Corporation | NYSE:SYK | $119.88 Billion | $345.81 |
| #170 | Medtronic PLC | NYSE:MDT | $111.60 Billion | $87.21 |
| #183 | Boston Scientific Corp | NYSE:BSX | $105.38 Billion | $71.28 |
Guerbet SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Guerbet SA's market cap moved from $666.73 Million to $ 102.04 Million, with a yearly change of -16.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €102.04 Million | -44.11% |
| 2025 | €182.58 Million | -48.73% |
| 2024 | €356.10 Million | +44.71% |
| 2023 | €246.08 Million | +16.55% |
| 2022 | €211.14 Million | -52.17% |
| 2021 | €441.49 Million | +14.18% |
| 2020 | €386.64 Million | -19.63% |
| 2019 | €481.09 Million | -17.50% |
| 2018 | €583.17 Million | -32.92% |
| 2017 | €869.40 Million | +12.91% |
| 2016 | €769.99 Million | +15.49% |
| 2015 | €666.73 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Guerbet SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $102.04 Million USD |
| MoneyControl | $102.04 Million USD |
| MarketWatch | $102.04 Million USD |
| marketcap.company | $102.04 Million USD |
| Reuters | $102.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.